GlassScriptPhysician profile
Morgan E Mingo
NPI 1841768207
$4,019.81
in general payments reported to CMS, 2019-2025
31 companies · $863 in 2025
The $863 reported for 2025 was more than what 82% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,212 · 2022: $975 · 2023: $416 · 2024: $555 · 2025: $863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,833.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,307.71 | 2021-2025 | |
| Pfizer INC. | $401.92 | 2021-2025 | |
| Averitas Pharma INC. | $353.04 | 2023-2025 | Qutenza |
| Novo Nordisk INC | $324.05 | 2021-2022 | |
| Astellas Pharma US INC | $198.62 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $169.93 | 2022 | |
| Curonix LLC | $118.15 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Collegium Pharmaceutical, INC. | $100.57 | 2023-2025 | Belbuca, Xtampza |
| Lilly USA, LLC | $98.88 | 2021-2024 | Emgality, Reyvow |
| Novartis Pharmaceuticals Corporation | $90.54 | 2021-2022 | |
| Si-Bone, INC. | $87.69 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $80.50 | 2025 | |
| Vanda Pharmaceuticals INC. | $77.96 | 2021-2022 | |
| Impel Pharmaceuticals LLC | $74.88 | 2025 | Trudhesa |
| Almatica Pharma LLC | $69.79 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $68.79 | 2021-2022 | |
| Grt US Holding, INC. | $59.55 | 2022 | |
| Lundbeck LLC | $58.93 | 2023-2024 | Vyepti |
| Eisai INC. | $39.62 | 2021-2022 | |
| Genentech USA, INC. | $33.89 | 2021-2022 | |
| Depuy Synthes Sales INC. | $26.21 | 2024 | Orthovisc, Monovisc |
| Astrazeneca Pharmaceuticals LP | $23.74 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $22.27 | 2023 | Zilretta, Iovera |
| Axsome Therapeutics, INC. | $21.57 | 2025 | Symbravo |
| Abbott Laboratories | $19.95 | 2024 | Eterna |
| E.R. Squibb & Sons, L.L.C. | $17.50 | 2022 | |
| Nalu Medical, INC. | $16.62 | 2022 | |
| Medtronic, INC. | $15.60 | 2023 | Intellis Adaptivestim |
| Ultragenyx Pharmaceutical INC. | $14.96 | 2021 | |
| Azurity Pharmaceuticals, INC. | $14.09 | 2023 | Horizant |
| Amgen INC. | $12.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Mingo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.